drugset / Trial / NCT00346619

Determining the Amount of Time Needed for Nelfinavir to Boost the Immune System in Adults

NCT00346619

Phase 1 Completed 25 enrolled Mayo Clinic
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Our group has shown that HAART increases the thymic production of naïve T cells in the healthy adult, thereby boosting the immune system. We propose to investigate the amount of and length of Nelfinavir therapy necessary to increase those cells in adults. Subjects will be treated with Nelfinavir, and blood will be sampled at variable times to determine the immune response in peripheral blood.

Timeline

Start
2005-10
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Nelfinavir Other / unclassified 1250 mg Oral

Indications

No indication recorded.